Abstract Details

Title The Long-term Risk of Clinically Definite Multiple Sclerosis after Optic Neuritis: Final Follow Up of the Optic Neuritis Treatment Trial Cohort

Topic

Presentation(s) (-)

Poster/Presentation
Number 001

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Eric R. Eggenberger, DO, FAAN (Mayo Clinic Florida)	Dr. Eggenberger has nothing to disclose.
Bhaskar Roy, MD, FAAN (Yale University)	Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda Pharmaceuticals. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Roy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for argenx. Dr. Roy has stock in Cabaletta bio. . The institution of Dr. Roy has received research support from Martin Shubik Fund for IBM at Yale University. The institution of Dr. Roy has received research support from Abcuro Pharmaceuticals. The institution of Dr. Roy has received research support from Immunovant.
	No disclosure on file
	No disclosure on file
	No disclosure on file

��ɫ��